Novem Group’s Halozyme HALO Stock Holding History

Novem Group’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$339K	Buy	3,067 +435	+17%	+$42K	0.03%	336
2026 Q2	$206K	Sell	2,632 -523	-17%	-$35.7K	0.02%	426
2026 Q1	$204K	Buy	+3,155	New	+$222K	0.02%	413
2025 Q4	–	Sell	-2,868	Closed	-$210K	–	440
2025 Q3	$210K	Buy	+2,868	New	+$191K	0.02%	396
2025 Q2	–	Sell	-22,407	Closed	-$1.43M	–	418
2025 Q1	$1.43M	Buy	22,407 +4,821	+27%	+$280K	0.2%	92
2024 Q4	$841K	Buy	+17,586	New	+$902K	0.12%	145

Other funds holding HALO

Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Novem Group's HALO Position: Q3 2026 in Review

Novem Group increased its Halozyme (HALO) stake by 17% in Q3 2026, buying an estimated $42K and bringing the position to 3,067 shares worth $339K. The position accounts for 0.03% of the portfolio, ranked #336.

Novem Group first reported a position in HALO in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.43M in Q1 2025. 456 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

Novem Group held 3,067 shares of Halozyme worth $339K as of Q3 2026.
Novem Group bought 435 Halozyme shares in Q3 2026, an estimated $42K.
Halozyme made up 0.03% of Novem Group's portfolio in Q3 2026, its #336 holding.
Novem Group first reported a position in Halozyme in Q4 2024 and has held it in 6 quarters since.
Novem Group's Halozyme position peaked at $1.43M in Q1 2025.
456 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Novem Group's 13F filing for Q3 2026, filed 19 Oct 2026.